Trial Profile

A Multicenter, Open-label Study to Evaluate the Safety and Efficacy of ICP-022 in Patients With Relapsed/Refractory Marginal Zone Lymphoma (MZL)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 22 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Orelabrutinib (Primary)
Indications Marginal zone B-cell lymphoma
Focus Registrational; Therapeutic Use
Sponsors InnoCare Pharma

Most Recent Events

16 Apr 2024 Status changed from active, no longer recruiting to completed.
15 Jun 2023 According to an InnoCare Pharma media release, the latest clinical data of this study assessing the safety and efficacy (Abstract Number: Nr.283) presented at the 17th International Conference on Malignant Lymphoma (ICML).
15 Jun 2023 Results presented in an InnoCare Pharma media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com